Literature DB >> 17353444

Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.

Jon G Keevil1, Michael W Cullen, Ronald Gangnon, Patrick E McBride, James H Stein.   

Abstract

BACKGROUND: Updated guidelines from the National Cholesterol Education Program Adult Treatment Panel III stratify patients into 5 groups of coronary heart disease (CHD) risk that determine intensity of lipid-lowering therapy. The present study assesses the distribution of low-density lipoprotein cholesterol (LDL-C) in the United States across the 5 groups of CHD risk as defined in the updated guidelines. METHODS AND
RESULTS: Subjects included 7399 individuals 20 to 79 years of age in the 1999 to 2002 National Health and Nutrition Examination Survey representing 171 million individuals in the United States. CHD risk, LDL-C levels, and goal achievement were determined per Adult Treatment Panel III guidelines. CHD risk assessment incorporated a medical condition review, risk factor summation, and Framingham Risk Score calculation. Percentages were weighted to represent population estimates, and SEs were adjusted for the survey design. The distribution of individuals by CHD risk included 61.1% at lower risk, 10.6% at high risk, and 5.7% at very high risk. From Adult Treatment Panel III criteria, only 5.4% of the population was at "intermediate" risk. Two thirds (66.3%) met their Adult Treatment Panel III-defined LDL-C goal. Of those at high and very high risk, 23% and 26%, respectively, met the goal of LDL-C <100 mg/dL, whereas only 3.1% and 4.6% had an LDL-C <70 mg/dL (or non-high-density lipoprotein C <100 mg/dL).
CONCLUSIONS: Most adult US residents are at lower 10-year CHD risk and meet risk-adjusted LDL-C goals. However, large portions of the high-risk population are undertreated. The commonly described population at intermediate risk is small. A novel method of identifying patients who might benefit from additional testing to determine their treatment strategy is provided.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17353444     DOI: 10.1161/CIRCULATIONAHA.106.645473

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  23 in total

1.  Using stress testing to guide primary prevention of coronary heart disease among intermediate-risk patients: a cost-effectiveness analysis.

Authors:  Benjamin Z Galper; Andrew Moran; Pamela G Coxson; Mark J Pletcher; Paul Heidenreich; Lawrence D Lazar; Nicolas Rodondi; Y Claire Wang; Lee Goldman
Journal:  Circulation       Date:  2011-12-05       Impact factor: 29.690

Review 2.  Current Science on Consumer Use of Mobile Health for Cardiovascular Disease Prevention: A Scientific Statement From the American Heart Association.

Authors:  Lora E Burke; Jun Ma; Kristen M J Azar; Gary G Bennett; Eric D Peterson; Yaguang Zheng; William Riley; Janna Stephens; Svati H Shah; Brian Suffoletto; Tanya N Turan; Bonnie Spring; Julia Steinberger; Charlene C Quinn
Journal:  Circulation       Date:  2015-08-13       Impact factor: 29.690

3.  A modified formula for calculating low-density lipoprotein cholesterol values.

Authors:  Yunqin Chen; Xiaojin Zhang; Baishen Pan; Xuejuan Jin; Haili Yao; Bin Chen; Yunzeng Zou; Junbo Ge; Haozhu Chen
Journal:  Lipids Health Dis       Date:  2010-05-21       Impact factor: 3.876

4.  Does LDL-C Estimation Using Anandaraja's Formula Give a Better Agreement with Direct LDL-C Estimation than the Friedewald's Formula?

Authors:  Shalini Gupta; Minni Verma; Kamaljit Singh
Journal:  Indian J Clin Biochem       Date:  2012-03-24

5.  Differences in cholesterol management among states in relation to health insurance and race/ethnicity across the United States.

Authors:  Stanley H Hsia; Monica L Desnoyers; Martin L Lee
Journal:  J Clin Lipidol       Date:  2013-04-03       Impact factor: 4.766

6.  Translating cholesterol guidelines into primary care practice: a multimodal cluster randomized trial.

Authors:  Charles B Eaton; Donna R Parker; Jeffrey Borkan; Jerome McMurray; Mary B Roberts; Bing Lu; Roberta Goldman; David K Ahern
Journal:  Ann Fam Med       Date:  2011 Nov-Dec       Impact factor: 5.166

7.  Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry).

Authors:  Anselm K Gitt; Claus Jünger; Christina Jannowitz; Barbara Karmann; Jochen Senges; Kurt Bestehorn
Journal:  Clin Res Cardiol       Date:  2010-10-21       Impact factor: 5.460

8.  Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.

Authors:  Peter H Jones; Harold E Bays; Michael H Davidson; Maureen T Kelly; Susan M Buttler; Carolyn M Setze; Darryl J Sleep; James C Stolzenbach
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

9.  Who exceeds ATP-III risk thresholds? Systematic examination of the effect of varying age and risk factor levels in the ATP-III risk assessment tool.

Authors:  Margaret W Cavanaugh-Hussey; Jarett D Berry; Donald M Lloyd-Jones
Journal:  Prev Med       Date:  2008-07-29       Impact factor: 4.018

10.  Ethanol extract of Zhongtian hawthorn lowers serum cholesterol in mice by inhibiting transcription of 3-hydroxy-3-methylglutaryl-CoA reductase via nuclear factor-kappa B signal pathway.

Authors:  Hai-Jie Hu; Xue-Gang Luo; Qing-Qing Dong; Ai Mu; Guo-Long Shi; Qiu-Tong Wang; Xiao-Ying Chen; Hao Zhou; Tong-Cun Zhang; Li-Wen Pan
Journal:  Exp Biol Med (Maywood)       Date:  2016-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.